RT Journal Article
T1 Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice.
A1 Biagetti, Betina
A1 Herance, J R
A1 Ferrer, Roser
A1 Aulinas, Anna
A1 Palomino-Schätzlein, Martina
A1 Mesa, Jordi
A1 Castaño, J P
A1 Luque, Raul M
A1 Simo, Rafael
K1 Acromegaly
K1 Amino acids
K1 Branched chain
K1 Insulin resistance
K1 Metabolomics
K1 Muscular weakness
AB Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities. The present study was aimed at identifying metabolites that could be used as biomarkers for a better disease phenotyping. For this purpose, metabolic fingerprint using an untargeted metabolomic approach was examined in serum from 30 patients with acromegaly and 30 age-matched controls. Patients with acromegaly presented fewer branched-chain amino acids (BCAAs) compared to the control group (valine: 4.75 ± 0.87 vs. 5.20 ± 1.06 arbitrary units (AUs), p < 0.05; isoleucine: 2.54 ± 0.41 vs. 2.80 ± 0.51 AUs; p < 0.05). BCAAs were also lower in patients with active disease compared to patients with normal levels of IGF-1 with or without medical treatment. GH, but not IGF-1, serum levels were inversely correlated with both valine and isoleucine. These findings indicate that low levels of BCAAs represent the main metabolic fingerprint of acromegaly and that GH, rather than IGF-1, might be the primary mediator. In addition, our results suggest that the assessment of BCAAs could help to identify active disease and to monitor the response to therapeutic strategies.
PB MDPI
SN 2077-0383
YR 2019
FD 2019-09-23
LK http://hdl.handle.net/10668/14561
UL http://hdl.handle.net/10668/14561
LA en
NO Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schätzlein M, Mesa J, et al. Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice. J Clin Med. 2019 Sep 26;8(10):1549
DS RISalud
RD Apr 8, 2025